Replies to post #138564 on Biotech Values

[DewDiligence]

TYZM fails again in phase-3 trial for postoperative ileus:

http://finance.yahoo.com/news/tranzyme-pharma-norgine-announce-top-203000773.html

Consistent with the ULISES 007 data released in March 2012, ULISES 008 did not meet the primary and secondary endpoints as there was no statistical difference between the ulimorelin and placebo groups. The two trials were identical in design and population.